Efficacy News and Research

RSS

Harnessing the power of gut bacteria to enhance cancer immunotherapy effectiveness

A comprehensive new review reveals both the promise and challenges of using fecal microbiota transplantation (FMT) to enhance cancer immunotherapy effectiveness.

30 Jul 2025

Intratumoral microbial metabolites shape the tumor microenvironment and impact immunotherapy

The tumor microenvironment (TME) represents a highly complex system that encompasses cellular components (such as cancer cells, stromal cells, and immune cells) and non-cellular components (such as blood vessels and signaling molecules).

30 Jul 2025

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Discover how twin screw granulation enables continuous, solvent free drug amorphization—expert insights from Thermo Fisher Scientific’s Maggie Richter.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 30 Jul 2025

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

29 Jul 2025

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.

29 Jul 2025

Understanding immune drift in biologic therapy for inflammatory skin diseases

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).

28 Jul 2025

Advancing precision medicine in colorectal cancer with multi-omics approaches

Colorectal cancer is among the most prevalent and lethal malignancies worldwide, with liver metastases occurring in nearly one-third of patients and accounting for a major share of cancer-related deaths.

28 Jul 2025

Common plant virus shows powerful potential as cancer immunotherapy

A virus that typically infects black-eyed peas is showing great promise as a low-cost, potent cancer immunotherapy-and researchers are uncovering why.

28 Jul 2025

Cardiologists urged to prioritize potent statins in managing LDL cholesterol

There is broad consensus that the overall body of evidence shows lowering LDL (low-density lipoprotein) cholesterol provides both statistically significant and clinically meaningful benefits in treating and preventing cardiovascular disease.

28 Jul 2025

Study reveals a strong link between early childhood adversities and depression in older Canadians

A new study of 3,500 Canadians aged 55 and older revealed a strong association between early childhood adversities and depression.

28 Jul 2025

Promising new male birth control pill could be taken every three days

YCT-529, a novel non-hormonal male contraceptive, demonstrates safety and tolerability in early trials, offering a potential solution for male birth control.

28 Jul 2025

Common vegetable oils speed up skin regeneration

Investigating vegetable oils, this study reveals their effects on skin cell proliferation and migration, emphasizing the role of fatty acid composition.

28 Jul 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

New study shows potent effects of desert berry extract (NRK-C)

The global diabetes epidemic continues its relentless march, with projections suggesting 750 million sufferers by 2045. While current medications help control symptoms, they often come with undesirable side effects and don't address the root causes of metabolic dysfunction. The search for better solutions has turned scientists toward natural drugs, where traditional remedies may hold untapped potential.

26 Jul 2025

VCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl transferase-1 (GGT-1), for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often treatment-resistant T-cell lymphoma.

26 Jul 2025

Gene-edited mosquitoes slash malaria spread 93% using self-propagating shield

Scientists engineered a naturally occurring genetic variant (Q224) in Anopheles stephensi mosquitoes, making them highly resistant to malaria parasites without affecting fitness. A novel gene-drive system rapidly spread this protective trait through lab mosquito populations, offering a potential breakthrough for malaria control.

24 Jul 2025